ArticleDrug, healthcare and patient safety2012
Antipsychotic agents: efficacy and safety in schizophrenia.
Article in Drug, healthcare and patient safety, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 27 citations in OpenAlex.
- Trial
- A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor.Psychopharmacology · 2016Trial
- Article
- Linking Genome-Wide Association Studies to Pharmacological Treatments for Psychiatric Disorders.JAMA psychiatry · 2025Article
- Diagnosis of Schizophrenia and Its Subtypes Using MRI and Machine Learning.Brain and behavior · 2025Article
- Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier.Pharmaceutics · 2021Review
- A Review of Studies Leveraging Multimodal TMS-fMRI Applications in the Pathophysiology and Treatment of Schizophrenia.Frontiers in human neuroscience · 2021Review
- Antioxidant Properties of Second-Generation Antipsychotics: Focus on Microglia.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Effects of different types of sensory signals on reaching performance in persons with chronic schizophrenia.PloS one · 2020Article
- Investigational and Therapeutic Applications of Transcranial Magnetic Stimulation in Schizophrenia.Current psychiatry reports · 2019Review
- Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries.European journal of clinical pharmacology · 2019Article
- Infusions of Nerve Growth Factor Into the Developing Frontal Cortex Leads to Deficits in Behavioral Flexibility and Increased Perseverance.Schizophrenia bulletin · 2018Article
- Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future.Current topics in medicinal chemistry · 2016Review
- Temporomandibular disorders in patients with schizophrenia using antipsychotic agents: a discussion paper.Drug, healthcare and patient safety · 2014Review
- Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia.Neuropsychiatric disease and treatment · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antipsychotics have provided a great improvement in the management of people with schizophrenia. The first generation antipsychotics could establish the possibility of managing many psychotic subjects in an outpatient setting. With the advent of the second (SGA) and third generation antipsychotics (TGA), other psychiatric disorders such as bipolar depression, bipolar mania, autism, and major depressive disorder have now been approved for the use of these drugs for their treatment. Also, the administration of more specific assessment tools has allowed for better delineation of the repercussions of these drugs on symptoms and the quality of life of patients who use antipsychotic agents. In general, the SGA share similar mechanisms of action to achieve these results: dopamine-2 receptor antagonism plus serotonin-2A receptor antagonism. The TGA (eg, aripiprazole) have partial agonist activity at the dopamine-2 receptor site, and are also called dopaminergic stabilizers. The pharmacological profile of SGA and TGA may provide better efficacy against negative symptoms, and are less likely to produce extrapyramidal symptoms; however, the SGA and TGA are associated with many other adverse events. The clinician has to balance the risks and benefits of these medications when choosing an antipsychotic for an individual patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.